Navigation Links
Quest PharmaTech Receives Support from National Research Council's Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer

EDMONTON, April 22 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. ("Quest" or the "Company") is pleased to announce that it will receive generous support from NRC-IRAP towards the development of Quest's Sonodynamic Therapy (SDT) for oncology applications.

Sonodynamic Therapy arises out of the Company's long-term interest in Hypocrellin-based photodynamic therapy for oncology and skin diseases. The Company's lead compound, SL017, with Intense Pulse Light is currently being evaluated for hair removal applications in a 90 patient Phase II clinical trial. A second product, SL052, in combination with laser light activation is in late-stage pre-clinical development for prostate cancer treatment and is scheduled to enter a Phase I clinical trial during the second half of 2008. Both products can also be activated by ultrasound.

SDT involves the administration of non-toxic pharmaceutical agents which may be activated deep within the body, by ultrasound, which is in itself non-toxic. The attractive features of this technology for cancer treatment emerges from the ability to focus the ultrasound energy on malignancy sites buried deep in tissues and to locally activate a preloaded sonosensitizer. The goal of SDT is to provide effective and specific eradication or control of tumors, while minimizing or eliminating toxicity and morbidity to the remainder of the patient.

Financial support of up to $198,362 from NRC/IRAP will help the Company to obtain proof-of-concept for the use of its proprietary Hypocrellin-based compounds for Sonodynamic Therapy applications. Technology development will also include new formulations involving nanoparticles and development of unique ultrasound transducers. In addition to the financial support, IRAP will continue to play an advisory role in acquiring complementary technologies to commercialize SDT-based products. The overall program will be coordinated by Dr. Gerald Miller, Executive Consultant to the Company and former Research Professor at the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta.

"It is the strategy of the Company to add value to its oncology program by expanding the utility of Hypocrellin-based products for Immuno Photodynamic Therapy and Sonodynamic Therapy applications", said Dr. Madi R. Madiyalakan, CEO of the Company. "The current funding from NRC/IRAP, and recently signed collaborative research agreement with British Columbia Cancer Agency will help us accomplish that objective in an efficient manner", added Dr. Madiyalakan.

The Company also announces that it has retained the consulting services of Dr. Graeme Boniface to help accelerate its clinical trial program. Dr. Boniface was previously Senior Director of Clinical research at QLT Inc. in Vancouver, where he led the clinical development of several photosensitizers for oncology indications. Dr. Boniface brings more than 25 years of experience in conducting clinical trials throughout the world. Additionally, the Company believes that its partnership with Paramount Biosciences for dermatology program will help achieve its long-term growth objectives, including additional clinical trials for dermatology applications.

About Quest PharmaTech Inc: Quest PharmaTech Inc. is a publicly traded (TSX Venture Exchange: QPT), Alberta-based pharmaceutical company committed to build shareholder value through discovery, development and commercialization of new pharmaceutical products. It is developing a series of products for the treatment of cancer and dermatological conditions based on its unique photodynamic and sonodynamic therapy platform.

"TSX Venture Exchange has neither approved nor disapproved of the

information contained herein."

SOURCE Quest PharmaTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. has initiated coverage on the following equities: ... (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing their ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. ... a free webinar on Performing Quality Investigations: Getting to Root Cause. ... at no charge. , Incomplete investigations are still a major concern to the ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
(Date:6/22/2016)... 22, 2016 Cell Applications, Inc. and ... to produce up to one billion human induced ... one week. These high-quality, consistent stem cells enable ... and spend more time doing meaningful, relevant research. ... high-volume manufacturing process that produces affordable, reliable HiPSC ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
Breaking Biology News(10 mins):